Alluvi, previously BI 4744, offers a notable advance in obesity care. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates impressive efficacy in patient trials, arguably surpassing https://alluvi027348.taletrueblog.com/665588/alluvi-a-in-depth-examination-into-retatrutide-s-prospects